Madam Speaker, as the conference for a Medicare prescription drug benefit gets under way, we are reminded how difficult this compromise will be and that the bills in both the House and the other Chamber will leave many seniors with many…
Madam Speaker, as the conference for a Medicare prescription drug benefit gets under way, we are reminded how difficult this compromise will be and that the bills in both the House and the other Chamber will leave many seniors with many high prescription drug costs.
We have a bipartisan bill with the gentleman from Minnesota (Mr. Gutknecht), the gentlewoman from Missouri (Mrs. Emerson) and myself, other Republicans and Democrats from both
sides of the aisle, people who do not usually see issues alike and come together, but find a common set of values in this legislation that opens up the market on prescription drugs to Canada and other, European countries.
Through competition, we would lower prices, and the truth is for all too long the elderly and the American families in our country, in our districts, have been subsidizing the poor, starving French and German and Swiss and English and Canadians who have artificially low prices. And we have been charged overwhelmingly; we pay in this country top, premium prices for prescription drugs.
What I want to do and what this legislation would call for in a bipartisan fashion would open up the market. We have a closed market now. We do not have that type of closed market when it comes to cars, when it comes to steel, when it comes to food products, when it comes to software, when it comes to all types of products; but in the area of pharmaceuticals, we have a closed market, and Americans are paying top, premium prices.
Two weeks ago Families USA released a study. Prices for the top 50 drugs most commonly prescribed to seniors increased at 3\1/2\ times the rate of inflation. Total spending for senior citizens on prescription drugs rose an estimated 44 percent between 2000 and 2003. The only means available to reduce prices of prescription drugs which our families and our seniors pay at the local pharmacy is to have real competition.
In Canada, in England, France, Germany, many of the folks there pay 30, 40, 50 percent less for the same name-brand drugs. Why? Because the pharmaceutical industry can, here in America, charge a premium. We pay the highest prices, and the only way we pay the highest prices is so they can afford to pay the lowest prices.
In my view, it is time that we have legislation that ensures open access, open markets in the area of pharmaceutical medication, and through that free market, we will reduce prices.
Second, if you are about to embark on the largest expansion of entitlement in over 40 years, $400 billion, would you not want to ensure that the taxpayers got the best bang for their buck? $400 billion we are about to ask the taxpayers to spend, and yet we do nothing to protect the taxpayers or the elderly to get the best price for that.
Now, this question is whether we will go over 10 years. My view is, if we are about to ask them to pay $400 billion to subsidize prescription drugs for our elderly, we should ensure that if we can save 25 percent, 30 percent, 40 percent, which is what you can do through market access, we should afford the taxpayers and the elderly reduced, affordable prices.
One, guarantee the taxpayers of this country the best prices their money can buy. Two, ensure that our elderly, who are on fixed incomes, get the types of prices that are now being paid for the same medications in France, Germany, England or Canada. We will then need not ask our seniors to pay the premium price.
Now, one myth that the pharmaceutical industry keeps spreading is that somehow this is about safety, that the FDA cannot do this. The truth is, if somebody tells you it is not about money, it is about money, and that is what is at stake here. The pharmaceutical industry understands that for a very long time they have had a protective market here in the United States. If we were to open up the market, they would have real competition and the prices would drop.
Second, I think it is very, very important. I understand the political process, as everybody does. We should all know that the pharmaceutical industry has about 600-some-odd lobbyists here in town. It is about a lobbyist and a half for each Member of the United States Congress. They give out and support through donations and other entertainment close to $200 million and support the candidates and Members of Congress through entertainment and donations. But the $200 million we get, and there is nothing wrong with that, that is what they do, that is what they advocate for their position.
But the $200 million they give out in donations, contributions and entertainment pales in comparison to the $200 billion our seniors have been overcharged.
When this vote occurs this week, each Member will ask to speak and vote on behalf of the people of their district, and the question will be, will we continue a practice in which our elderly are overcharged by $200 billion, our taxpayers will be overcharged and pay the top, premium price rather than the most affordable price; or will we continue to accept these types of donations and entertainment and put our interests above the people that we represent?
I have full faith in my colleagues here that we will stand up for the people we represent, because we came here not just to be another vote but to be a voice for their values. Their values say, it is time to ensure that our taxpayers and our elderly stop subsidizing those in Europe and in Canada with more affordable prices while we in America pay premium prices.